News

– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will potentially expand toripalimab opportunity into large indications with high unmet need – REDWOOD CITY,

REDWOOD CITY, Calif. , Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Citi's 2023 18th Annual BioPharma Conference in Boston on Wednesday, September 6, 2023 ,

REDWOOD CITY, Calif. , Aug. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 20, 2023 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 77,000 shares of

– Net revenue rose 81% from prior quarter to $58.7 million   – – CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter – – UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July – – Planned merger with Surface Oncology expected to significantly advance

REDWOOD CITY, Calif. , July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023 . Starting at 5:00 pm ET on August 02, 2023, Coherus’ management

REDWOOD CITY, Calif. , July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 20, 2023 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 187,000 shares of

 – Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches – REDWOOD CITY, Calif. , July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the appointment to

First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to Humira Innovative distribution plan provides employers a low-cost, high-quality treatment option from Coherus and the

–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85%   compared to Humira® – – YUSIMRY™ meets high unmet need by providing patients, employers, physicians and payers with low-cost access to adalimumab treatment – REDWOOD CITY, Calif.

REDWOOD CITY, Calif. , June 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 20, 2023 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 48,000 shares of

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus’ I-O pipeline with anti-IL-27 and anti-CCR8 clinical

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in the US; if approved, toripalimab will address a critical unmet need – REDWOOD CITY, Calif.

–    YUSIMRY™ (adalimumab-aqvh) will be the first   biologic product offered by the Mark Cuban Cost Plus Drug Company  – –    YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees  – DALLAS, Texas and REDWOOD CITY, Calif.

List price of $995 per carton for two 40 mg/0.8 mL autoinjectors REDWOOD CITY, Calif. , June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023 * with a list price of $995 per

–   UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need by giving providers a new, innovative option that offers patients greater choice, independence

REDWOOD CITY, Calif. , May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share.

REDWOOD CITY, Calif. , May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option

– UDENYCA ® autoinjector approved and ready for May 2023 launch – – CIMERLI ® product-specific Q-code now facilitating electronic reimbursement following April 1 activation – – FDA inspection of toripalimab manufacturing site scheduled for May 2023 – – Toripalimab launch anticipated in Q3 2023, if

REDWOOD CITY, Calif. , May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Bank of America Merrill Lynch Global Healthcare 2023 Conference in Las Vegas on Thursday, May

REDWOOD CITY, Calif. , May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023 . Starting at 5:00 pm ET on May 8, 2023 , Coherus’ management team will

SHANGHAI, China and REDWOOD CITY, Calif. , April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data presentations of four toripalimab pivotal clinical

– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 – – FDA is planning the toripalimab manufacturing site inspection in Q2 2023 – – UDENYCA ® autoinjector approved by FDA; UDENYCA ® on-body injector under review by FDA – – Planning underway for potential

- UDENYCA ® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy - - An additional presentation, the UDENYCA ® proprietary on-body

REDWOOD CITY, Calif. , March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43rd Annual Cowen Health Care Conference on Tuesday, March 7 th at 2:10 p.m.

REDWOOD CITY, Calif. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023 . Starting at 5:00 pm ET on March 6, 2023 , Coherus’

Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC SHANGHAI, China and REDWOOD CITY, Calif. , Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd

- Q-Code assigned to CIMERLI ® for Medicare claims processing effective for dates of service on and after April 1, 2023 - - COHERUS Solutions™ patient services hub is available to facilitate successful access and reimbursement - REDWOOD CITY, Calif. , Feb.

REDWOOD CITY, Calif. , Feb. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 1, 2023 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares

Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential REDWOOD CITY, Calif. , Jan. 09, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences , Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge

REDWOOD CITY, Calif. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 , at 8:15 a.m. Pacific Time .